enGene Therapeutics Inc
NASDAQ:ENGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
enGene Therapeutics Inc
NASDAQ:ENGN
|
CA |
|
Bank First Corp
NASDAQ:BFC
|
US |
|
C
|
Cancambria Energy Corp
XTSX:CCEC
|
CA |
|
DHT Holdings Inc
NYSE:DHT
|
BM |
Intrinsic Value
Is ENGN undervalued or overvalued?
See the intrinsic value estimate for enGene Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ENGN looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with ENGN’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What enGene Therapeutics Does
enGene Holdings is a clinical-stage biotechnology company that develops non-viral gene medicines for diseases with high unmet need. Its main focus is a bladder treatment for people with non-muscle invasive bladder cancer, but the broader idea is the same: deliver genetic material directly to a target tissue so the body can make a therapeutic effect without using a viral vector.
- Headquarters
- Canada CA
- Employees
- 82
- IPO date
- Dec 10, 2021
Earnings Waterfall
enGene Therapeutics Inc
The intrinsic value for enGene Therapeutics Inc (ENGN) under the Base Case is hidden USD.
Compared with the current market price of 1.555 USD, the stock appears hidden.